These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32780457)

  • 1. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.
    Udagawa C; Zembutsu H
    Cancer Sci; 2020 Oct; 111(10):3445-3457. PubMed ID: 32780457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of Adverse Drug Reactions.
    Osanlou O; Pirmohamed M; Daly AK
    Adv Pharmacol; 2018; 83():155-190. PubMed ID: 29801574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
    Chan SL; Jin S; Loh M; Brunham LR
    Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers.
    Sahu RK; Singh K; Subodh S
    Curr Drug Metab; 2015; 16(7):538-52. PubMed ID: 26264201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.
    Tohkin M; Ishiguro A; Kaniwa N; Saito Y; Kurose K; Hasegawa R
    Drug Metab Pharmacokinet; 2010; 25(2):122-33. PubMed ID: 20460818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical association between pharmacogenomics and adverse drug reactions.
    Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
    Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying the common genetic networks of ADR (adverse drug reaction) clusters and developing an ADR classification model.
    Hwang Y; Oh M; Jang G; Lee T; Park C; Ahn J; Yoon Y
    Mol Biosyst; 2017 Aug; 13(9):1788-1796. PubMed ID: 28702565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
    Zhang Z; Wu Y; Tan NC; Jiang Y
    Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics in clinical dermatology.
    Ameen M; Smith CH; Barker JN
    Br J Dermatol; 2002 Jan; 146(1):2-6. PubMed ID: 11841360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions: role of pharmacogenomics.
    Severino G; Del Zompo M
    Pharmacol Res; 2004 Apr; 49(4):363-73. PubMed ID: 15202516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to Consider Rare Genetic Variants in Personalized Drug Therapy.
    Lauschke VM; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2018 May; 103(5):745-748. PubMed ID: 29313952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents.
    Iemmolo R; La Cognata V; Morello G; Guarnaccia M; Arbitrio M; Alessi E; Cavallaro S
    Biosensors (Basel); 2020 Dec; 10(12):. PubMed ID: 33317085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline genetic variants with implications for disease risk and therapeutic outcomes.
    Pasternak AL; Ward KM; Luzum JA; Ellingrod VL; Hertz DL
    Physiol Genomics; 2017 Oct; 49(10):567-581. PubMed ID: 28887371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and Challenges in Pharmacogenomics.
    Van Driest SL; Cascorbi I
    Clin Pharmacol Ther; 2021 Sep; 110(3):529-532. PubMed ID: 34412159
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenetically tailored treatments for heart disease.
    Vafiadaki E; Arvanitis DA; Kranias EG; Sanoudou D
    Curr Pharm Des; 2010; 16(20):2194-213. PubMed ID: 20459385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Databases in the area of pharmacogenetics.
    Sim SC; Altman RB; Ingelman-Sundberg M
    Hum Mutat; 2011 May; 32(5):526-31. PubMed ID: 21309040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first steps towards the era of personalised vaccinology: predicting adverse reactions.
    Pellegrino P; Falvella FS; Perrone V; Carnovale C; Brusadelli T; Pozzi M; Antoniazzi S; Cheli S; Perrotta C; Clementi E; Radice S
    Pharmacogenomics J; 2015 Jun; 15(3):284-7. PubMed ID: 25287071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.